Merck KGaA : FY review -Outlook better on healthcare, but more cautious on life sciences
>Q4 review – Slight beat in Q4 - Q4 2023 revenues of € 5,225m (-7.7% y-o-y) were 0%/+2% vs ODDO BHF/consensus. The organic decline was -2.9%, (ODDO BHF -3.8%). EBITDA pre of € 1,293m (-19.8% y-o-y, margin 24.7%) was 5%/1% better than ODDO BH/consensus. Core EPS was € 1.85 some 0%/3% ahead of expectations on a lower tax rate. For 2024, the company expects slight to modest organic growth with a forex headwind of 0% to -3% (ODDO BHF 4.9% organic growth, consensus 1.8% in...Merck is a global science and technology company based in Germany. Co. diversifies its activities into four business divisions: Merck Serono, Consumer Health, Performance Materials and Merck Millipore. The Merck Serono develops, manufactures and markets prescription drugs to treat cancer, multiple sclerosis, infertility, growth disorders, and selected cardiovascular and metabolic diseases. The Consumer Health manufactures and markets over-the-counter drugs addressing health themes such as mobility, women's and children's health, cough and cold. Performance Materials is a specialty chemicals business. The Merck Millipore is the supplier of products and services for the life science industry.
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.